Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Aug;205(2):534-541.
doi: 10.1111/bjh.19470. Epub 2024 Apr 17.

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Cameron S Lewis  1   2 , Greta Joy  3   4 , Paw Jensen  5 , Allison Barraclough  6   7 , Nunzio Franco  8 , Dipti Talaulikar  8   9 , Eliza A Hawkes  6   10 , Tarec Christoffer El-Galaly  5   11   12 , Diego Villa  3 , Michael Dickinson  2   13 , John F Seymour  2   13 , Chan Y Cheah  1
Affiliations
Multicenter Study

Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study

Cameron S Lewis et al. Br J Haematol. 2024 Aug.

Abstract

Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) accounts for the majority of extra-nodal DLBCL. Even so, literature is lacking on early, localised presentations. We studied a cohort of patients with stage I disease, diagnosed between 2006 and 2018, from six centres between Australia, Canada and Denmark. Our goal was to characterise outcomes, review treatment and investigate the role of interim positron emission tomography (iPET). Thirty-seven eligible patients were identified. The median duration of follow-up was 42.2 months. All received chemoimmunotherapy with 91.9% (n = 34) given rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP). 35.1% (n = 13) underwent consolidative radiotherapy. Eighteen patients were H. pylori positive and 11 had the documentation of H. pylori eradication therapy. The 4-year progression-free survival and overall survival of R-CHOP was 88% (95% CI: 71-95) and 91% (95% CI: 75-97) respectively. All patients who achieved a partial metabolic response or complete metabolic response on iPET went on to achieve complete response at the end of treatment. R-CHOP-based therapy with iPET assessment appears to offer favourable outcomes, with radiotherapy and H. pylori eradication therapy implemented on a case-by-case basis.

Keywords: DLBCL; extranodal lymphoma; gastric DLBCL; gastric lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non‐Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19:3861–3873.
    1. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–2473.
    1. Engels EA. Infectious agents as causes of non‐Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev. 2007;16:401–404.
    1. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350:239–248.
    1. Hirabayashi M, Traverse‐Glehen A, Combes J‐D, Clifford GM, de Martel C. Estimating the prevalence of Epstein‐Barr virus in primary gastric lymphoma: a systematic review and meta‐analysis. Infect Agent Cancer. 2023;18:8.

Publication types

MeSH terms

Supplementary concepts